Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

St Mary's Hospital
London
W2 1NY


Find another location


Questions to ask
Skip to Main Content
Keep up to date

Sign up for news and information about taking part and shaping research.

Back

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Stopped

Open to: All Genders

Age: 18 Years - N/A

London London London Birmingham London

Medical Conditions

HIV Infections

This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.


Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and emtricitabine (FTC). This study will examine whether including apricitabine as part of patients' treatment is more effective than including lamivudine,when patients change treatment because of drug resistance.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2008

Jan 2010

Interventional

Intervention Type : Drug
Intervention Description : 800mg BID apricitabine orally for 48 weeks

Intervention Arm Group : 1

Intervention Type : Drug
Intervention Description : 150mg BID lamivudine orally for 48 weeks

Intervention Arm Group : 2

You can take part if:



Inclusion Criteria: - HIV-1 positive with M184V/I mutation in reverse transcriptase; - 18 years of age or older; - Currently taking lamivudine (3TC) or emtricitabine (FTC) Exclusion Criteria: - Female patients who are pregnant or breastfeeding; - Current hepatitis B virus (HBV) infection; - Current treatment for hepatitis C virus infection; - Renal function not adequate




You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • St Mary's Hospital
    London
    W2 1NY
  • Royal Free Hospital
    London
    NW3 2QG
  • St Bartholomew's Hospital
    London
    EC1A 7BE
  • Birmingham Heartlands Hospital
    Birmingham
    B9 5SS
  • Guy's King's & St. Thomas' School of Medicine
    London
    SE5 9RJ


The study is sponsored by Avexa


We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details

for Trial ID: NCT00612898

Last updated

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top
National Insitute for Health Research